CTOs on the Move

Strides

www.strides.com

 
Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets. The Company`s global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on “difficult to manufacture” products that are sold in over 100 countries.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.strides.com
  • 2 Tower Center Blvd Suite 1102
    East Brunswick, NJ USA 08816
  • Phone: 609.773.5000

Executives

Name Title Contact Details

Similar Companies

Paragon Laboratories

Paragon Laboratories is a Torrance, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sirtris Pharmaceuticals

Sirtris Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

4 dry skin natural products

4 dry skin natural products is a Nashville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Long Term Care Pharmacy Alliance

Long Term Care Pharmacy Alliance is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Everest Medicines

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.